BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 17587393)

  • 1. Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.
    Ristic S; Collober-Maugeais C; Cressier F; Tang P; Pecher E
    Diabetes Obes Metab; 2007 Jul; 9(4):506-11. PubMed ID: 17587393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.
    Ristic S; Collober-Maugeais C; Pecher E; Cressier F
    Diabet Med; 2006 Jul; 23(7):757-62. PubMed ID: 16842480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients.
    Marre M; Van Gaal L; Usadel KH; Ball M; Whatmough I; Guitard C
    Diabetes Obes Metab; 2002 May; 4(3):177-86. PubMed ID: 12047396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.
    Horton ES; Clinkingbeard C; Gatlin M; Foley J; Mallows S; Shen S
    Diabetes Care; 2000 Nov; 23(11):1660-5. PubMed ID: 11092289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
    Raskin P; Klaff L; McGill J; South SA; Hollander P; Khutoryansky N; Hale PM;
    Diabetes Care; 2003 Jul; 26(7):2063-8. PubMed ID: 12832314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
    Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
    J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin.
    Gerich J; Raskin P; Jean-Louis L; Purkayastha D; Baron MA
    Diabetes Care; 2005 Sep; 28(9):2093-9. PubMed ID: 16123472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
    Filozof C; Gautier JF
    Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
    Charbonnel B; Schernthaner G; Brunetti P; Matthews DR; Urquhart R; Tan MH; Hanefeld M
    Diabetologia; 2005 Jun; 48(6):1093-104. PubMed ID: 15889234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.
    Horton ES; Foley JE; Shen SG; Baron MA
    Curr Med Res Opin; 2004 Jun; 20(6):883-9. PubMed ID: 15200747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.
    Hirschberg Y; Karara AH; Pietri AO; McLeod JF
    Diabetes Care; 2000 Mar; 23(3):349-53. PubMed ID: 10868864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nateglinide alone or with metformin safely improves glycaemia to target in patients up to an age of 84.
    Weaver JU; Robertson D; Atkin SL
    Diabetes Obes Metab; 2004 Sep; 6(5):344-52. PubMed ID: 15287927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.
    Fonseca V; Grunberger G; Gupta S; Shen S; Foley JE
    Diabetes Care; 2003 Jun; 26(6):1685-90. PubMed ID: 12766094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nateglinide in combination with metformin in Chinese patients with type 2 diabetes mellitus: a post-marketing surveillance study.
    Yang JK; Wang L;
    Clin Drug Investig; 2013 Mar; 33(3):185-91. PubMed ID: 23338975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes.
    Schwarz SL; Gerich JE; Marcellari A; Jean-Louis L; Purkayastha D; Baron MA
    Diabetes Obes Metab; 2008 Aug; 10(8):652-60. PubMed ID: 17941876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of glycaemic control by nateglinide decreases systolic blood pressure in drug-naive patients with type 2 diabetes.
    González-Clemente JM;
    Eur J Clin Invest; 2008 Mar; 38(3):174-9. PubMed ID: 18257780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes.
    Israel MK; Istvan E; Baron MA
    Vasc Health Risk Manag; 2008; 4(6):1167-78. PubMed ID: 19337530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus.
    Salas M; Ward A; Caro J
    Clin Ther; 2002 Oct; 24(10):1690-705. PubMed ID: 12462297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).
    Gribble FM; Manley SE; Levy JC
    Diabetes Care; 2001 Jul; 24(7):1221-5. PubMed ID: 11423506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.